English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/213054
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:


Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series

AuthorsRuiz‐Villaverde, Ricardo; Dominguez‐Cruz, Javier; Armario‐Hita, Jose Carlos; Martinez‐Pilar, Leandro; Alcantara‐Luna, Sara; Pereyra‐Rodriguez, Jose Juan
KeywordsAtopic dermatitis
Issue DateAug-2019
PublisherJohn Wiley & Sons
CitationDermatologic Therapy 32(4): e12931 (2019)
AbstractAtopic dermatitis (AD) is a chronic, systemic disease that has a multifactorial etiology, where immune system disorders and epidermal barrier dysfunction are added to the influence of genetic and environmental factors. Dupilumab has been approved by United States and the European Union regulatory agencies in 2017 for the treatment of moderate‐to‐severe AD in adult patients who are candidates for systemic treatment. In this short report, we present a retrospective, multicentric study, in which five hospitals in Andalusia, Spain, have taken part. Our objective is to evaluate the safety and effectiveness of dupilumab in patients with moderate‐to‐severe AD treated with dupilumab with at least 52 weeks of follow‐up.
Publisher version (URL)http://dx.doi.org/10.1111/dth.12931
Identifiersdoi: 10.1111/dth.12931
issn: 1396-0296
e-issn: 1529-8019
Appears in Collections:(IBIS) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
Show full item record
Review this work

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.